SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549

                                   FORM 10-QSB


 [x]     QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
         EXCHANGE ACT OF 1934.

                  For the quarterly period ended July 31, 1997

                                       OR

 [ ]     TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
         ACT OF 1934.

         For the transition period from________________to________________


                         Commission file number 2-86360



                                INFORMEDICS, INC.
        (Exact name of small business issuer as specified in its charter)

            Oregon                                  93-0750571

    (State of incorporation)             (I.R.S. Employer Identification No.)



                       4000 Kruse Way Place, Bldg 3, Suite
                           300, Lake Oswego, OR 97035
                           --------------------------
                    (Address of principal executive offices)

                    Issuer's telephone number: (503) 697-3000

Check  whether  the issuer  (1) has filed all  reports  required  to be filed by
Section 13 or 15(d) of the Securities  Exchange Act of 1934 during the preceding
12 months (or for such shorter  period that the issuer was required to file such
reports),  and (2) has been subject to such filing  requirements for the past 90
days. Yes X No

Number of shares of Informedics, Inc. $.01 par value common stock outstanding as
of August 29, 1997: 2,650,307.



<PAGE>




                                INFORMEDICS, INC.


                         Part I - Financial Information




          The   information   included  herein  is  unaudited.   However,   such
 information  reflects all adjustments  (consisting solely of normal,  recurring
 adjustments)  which are, in the  opinion of  management,  necessary  for a fair
 presentation of the results of operations for the interim periods.  The interim
 financial  information and notes thereto should be read in conjunction with the
 Company's  latest annual report on Form 10-KSB.  The results of operations  for
 the nine months ended July 31, 1997 are not  necessarily  indicative of results
 to be expected for the entire year.



<PAGE>



INFORMEDICS,  INC.
STATEMENTS OF OPERATIONS
<TABLE>
<CAPTION>
                                                    Three Months Ended                                 Nine Months Ended
                                                         July 31,                                        July 31,

                                         -----------------------------------------     ---------------------------------------
                                                1997                1996                      1997               1996

                                         ------------------    -------------------     -------------------   -----------------
<S>                                            <C>                   <C>                    <C>                <C>    
REVENUE:
Product Sales                                   $  99,707             $  356,587             $  523,717         $  1,173,945
Customer Service and Support                      622,438                908,365              1,959,358            2,659,892
                                         ------------------    -------------------    -------------------    -----------------

Total Revenue                                     722,145              1,264,952              2,483,075            3,833,837
                                         ------------------    -------------------     ------------------    -----------------

COSTS AND EXPENSES:
Cost of Products Sold                              44,644                171,323                 98,305              538,563
Cost of Customer Service and Support
                                                  447,932                696,402              1,420,933            2,190,275
Selling & Administrative Expenses                 434,087                416,793              1,440,995            1,548,580
Depreciation & Amortization                        99,095                123,375                301,292              338,733
                                         ------------------    -------------------     ------------------    -----------------

Total Costs and Expenses                        1,025,758              1,407,893              3,261,525            4,616,151
                                         ------------------    -------------------     ------------------    -----------------

Operating  Loss                                  (303,613)              (142,941)              (778,450)            (782,314)
                                         ------------------    -------------------     ------------------    -----------------

OTHER INCOME (EXPENSE):
Interest Expense                                     (237)                  ----                 (4,759)                  (7)
Interest Income                                     7,219                  2,987                 26,918               11,652
 Other Income                                     169,777                   (186)               179,876                  (71)
                                         ------------------    -------------------     ------------------    -----------------

Total Other Income                                176,759                  2,801                202,035               11,574
                                         ------------------    -------------------     ------------------    -----------------

LOSS BEFORE INCOME TAXES                         (126,854)              (140,140)              (576,415)            (770,740)

INCOME TAX PROVISION                              688,025                (52,178)               688,025             (292,893)
(BENEFIT)
                                         ------------------    -------------------     ------------------    -----------------

NET LOSS                                     $   (814,879)            $  (87,962)         $  (1,264,440)       $    (477,847)
                                         ==================    ===================     ==================    =================

Weighted Average Number of Common
Shares Outstanding and Common Stock
Equivalents Outstanding
                                                2,650,307              2,646,381              2,650,307            2,644,995
                                         ==================    ===================     ==================    =================



LOSS PER SHARE                               $      (0.31)            $    (0.03)         $       (0.48)       $       (0.18)
                                         ==================    ===================     ==================    =================


 See Notes to Financial Statements.
</TABLE>
<PAGE>

INFORMEDICS, INC.
BALANCE SHEETS
<TABLE>
<CAPTION>

                                                                      July 31,             October 31,
ASSETS                                                                   1997                  1996
                                                                 -------------------    -------------------

<S>                                                                   <C>                     <C>    
CURRENT ASSETS:

Cash                                                                    $  259,154             $  323,217
Accounts Receivable, less allowance
   for doubtful accounts of $  22,727 in
   1997 and $ 28,439 in 1996                                               386,261                681,303
Inventories                                                                 20,021                 23,833
Prepaid Expenses and Other Current Assets                                   45,358                 36,150
Deferred Income Taxes                                                      101,271                182,483
Current Portion of Long-Term                                                11,928                 11,928
Receivable
Current Portion of Notes Receivable                                            ---                 54,095
                                                                 -------------------    -------------------

Total Current Assets                                                       823,993              1,313,009
                                                                 -------------------    -------------------
                                                                                                           

FIXED ASSETS:

Furniture and Fixtures                                                     134,282                134,282
Machinery and Equipment                                                    610,273                583,961
Automobiles                                                                    ---                 29,138
Leasehold Improvements                                                      26,738                 20,442
Other Fixed Assets                                                         142,545                136,805
                                                                 -------------------    -------------------
                                                                           913,838                904,628
Less accumulated depreciation and amortization                             760,218                672,300
                                                                 -------------------    -------------------

Total Fixed Assets                                                         153,620                232,328
                                                                 -------------------    -------------------


OTHER ASSETS:

Long-Term Account Receivable                                                33,796                 42,742
Notes Receivable                                                               ---                305,102
Software Development Costs,
   less accumulated  amortization of $ 724,445 in
   1997 and $ 542,884 in 1996                                              210,738                305,415
Covenants Not to Compete,
   less accumulated amortization of $ 491,274  in 1997
   and $ 479,698 in 1996                                                     2,772                 14,348
Deferred Income Taxes                                                        6,247                613,060
Other                                                                       39,799                 41,816
                                                                 -------------------    -------------------
Total Other Assets                                                         293,352              1,322,483
                                                                 -------------------    -------------------

TOTAL ASSETS                                                          $  1,270,965           $  2,867,820
                                                                 ===================    ===================

See Notes to Financial Statements
</TABLE>

<PAGE>



INFORMEDICS, INC.
BALANCE SHEETS
<TABLE>
<CAPTION>

   LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)                       July 31,              October 31,
                                                                          1997                   1996
                                                                    ------------------     ------------------
                                                                                                             
<S>                                                                       <C>                   <C>    
   CURRENT LIABILITIES:

   Accounts Payable and Accrued Expenses:
      Trade Accounts                                                       $  72,499             $  115,543
      Customer Deposits                                                        9,430                  4,120
      Accrued Wages, Payroll Taxes and Employee
         Benefits                                                            136,341                175,285
      Other Accrued Liabilities                                                8,705                    767
   Revolving Line of Credit (Note 2)                                             ---                125,000
   Deferred Revenue                                                        1,252,787              1,274,687
   Current Portion of Deferred Rent                                           13,033                 13,033
   Current Portion of Deferred Gain on Sale of Assets                            ---                 19,615
                                                                    ------------------     ------------------

   Total Current Liabilities                                               1,492,795              1,728,050

   LONG-TERM OBLIGATIONS:

   Deferred Rent                                                              20,636                 30,411
   Deferred Gain on Sale of Assets                                               ---                 87,375
                                                                    ------------------      ------------------

   Total Current Liabilities and
      Long-Term Obligations                                                1,513,431              1,845,836
                                                                    ------------------     ------------------
                                                                                                             

   STOCKHOLDERS' EQUITY (DEFICIT):

   Preferred Stock, $ .01 par value:
      authorized 5,000,000 shares;
      no shares outstanding                                                      ---                   ----
   Common Stock, $.01 par value:
      authorized 15,000,000 shares;
      shares outstanding:  2,650,307 in 1997 and 1996                         26,503                 26,503
   Capital in Excess of Par Value                                          1,914,213              1,914,213
   Note Receivable from Stockholder                                          (22,000)               (22,000)
   Accumulated Deficit                                                    (2,161,182)              (896,732)
                                                                    ------------------     ------------------
                                                                                                             

   Total Stockholders' Equity (Deficit)                                     (242,466)             1,021,984
                                                                    ------------------     ------------------
                                                                                                             

   TOTAL LIABILITIES AND STOCKHOLDERS'
      EQUITY (DEFICIT)                                                  $  1,270,965           $  2,867,820
                                                                    ==================     ==================
                                                                                                             

   See Notes to Financial Statements.
</TABLE>


<PAGE>


INFORMEDICS, INC.
STATEMENTS OF CASH FLOWS
<TABLE>
<CAPTION>

                                                                              Nine Months Ended July 31,

                                                                       -----------------------------------------
                                                                           1997                   1996
                                                                       -----------------------------------------

CASH FLOWS FROM OPERATING ACTIVITIES:
<S>                                                                      <C>                      <C>            
  Net loss                                                                $  (1,264,450)           $  (477,847)

ADJUSTMENTS  TO RECONCILE  NET LOSS TO NET
 CASH  PROVIDED BY (USED IN) OPERATING ACTIVITIES:
 Depreciation and Amortization                                                  301,292                338,733
 Provision for losses on (write off of) accounts receivable                      (5,712)               (18,899)
 Deferred Income Taxes                                                          606,813               (294,219)
 Tax benefits from stock options exercised                                          ---                  1,316
 Gain on Sale of Assets                                                        (106,990)                   ---
 Changes in Assets and Liabilities:
   Accounts Receivable                                                          309,700                102,888
   Income taxes receivable                                                       81,212                 29,077
   Inventories                                                                    3,812                 44,962
   Prepaid Expenses and Other Current Assets                                     (9,208)                55,634
   Accounts Payable and Accrued Expenses                                        (68,740)               (80,043)
   Notes Receivable                                                             359,197                    ---
   Deferred Revenue                                                             (21,900)               245,234
   Deferred Rent                                                                 (9,775)                (9,775)
                                                                       ------------------     ------------------
Net cash provided by (used in) operating activities                             175,251                (62,939)
                                                                       ------------------     ------------------

INVESTING ACTIVITIES:
 Property additions                                                             (40,019)               (69,921)
 Capitalized software development costs                                         (86,884)              (159,990)
 Other                                                                           12,589                  3,285
                                                                       ------------------     ------------------
 Net cash used in investing activities                                         (114,314)              (226,626)
                                                                       ------------------     ------------------
                                                                                                                

FINANCING ACTIVITIES:
 Decrease in revolving line of credit                                         (125,000)                100,000
 Proceeds from issuance of common stock                                             ---                  4,674
                                                                       ------------------     ------------------

 Net cash provided by (used in) financing activities                          (125,000)                104,674
                                                                       ------------------     ------------------

NET DECREASE IN CASH                                                           (64,063)               (184,891)

CASH AT BEGINNING OF PERIOD                                                     323,217                534,260
                                                                       ------------------     ------------------

CASH AT END OF PERIOD                                                        $  259,154              $ 349,369
                                                                       ==================     ==================

</TABLE>


<PAGE>


INFORMEDICS, INC.
STATEMENTS OF CASH FLOWS

<TABLE>
<CAPTION>

                                                                         Nine Months Ended July 31,
                                                                 -------------------------------------------
                                                                        1997                    1996
                                                                 -------------------------------------------
                                                                                                           
<S>                                                                      <C>                    <C>    
Supplemental Disclosures of Cash Flow
 Information:

Cash paid for:
 Interest                                                                 $  4,759           $      7

 Income Taxes Received                                                        ----            (29,077)


</TABLE>






See Notes to Financial Statements.

<PAGE>


INFORMEDICS, INC.
NOTES  TO FINANCIAL STATEMENTS


1.        SIGNIFICANT ACCOUNTING POLICIES

          Industry Segment
          ----------------

          The Company derives its revenue solely from the sales and servicing of
          microcomputer software and related hardware.

          Inventories
          -----------

          Inventories  are  stated  at the  lower  of cost or  market.  Specific
          identification is used to determine the costs of hardware and software
          inventory.

          Fixed Assets
          ------------

          Fixed Assets are stated at cost,  less  accumulated  depreciation  and
          amortization.  The  costs of fixed  assets  are  depreciated  over the
          estimated  useful  lives (two to five  years) of the assets  using the
          straight-line  method.  Leasehold  improvements are amortized over the
          term of the lease (five years).

          Customer Service and Support Revenue
          ------------------------------------

          Customer  service and support revenue  represents  revenue earned from
          hardware and software maintenance contracts, training, installation of
          new systems,  and general  software  support and programming  services
          provided to customers.  Under  renewable  maintenance  contracts,  the
          Company  provides,  for a term of  generally  not more  than one year,
          essentially all maintenance and repairs  resulting from the normal and
          intended  use  of  its  products.   Deferred  revenue  on  maintenance
          contracts is amortized  by the  straight-line  method over the life of
          the contracts.

          Revenue Recognition
          -------------------

          Revenue from sales of software and hardware is generally recorded when
          the product is shipped.  Revenue from custom software products,  which
          are  marketed  to  customers   primarily   under   perpetual   license
          arrangements,  is recorded at the time the  product is  installed  and
          accepted by the customer. Revenue from services other than maintenance
          contracts is recognized as performed.

          Income Taxes
          ------------

          Income taxes are accounted for using the  methodology  established  by
          Statement of Financial Accounting Standards (SFAS) No.109, "Accounting
          for Income Taxes", which requires an asset and a liability approach to
          financial  accounting and reporting for income taxes.  Deferred income
          tax assets and liabilities  are computed for  differences  between the
          financial  statement and tax bases of assets and liabilities that will
          result in taxable or  deductible  amounts in the  future.  A valuation
          allowance is established  when necessary to reduce deferred tax assets
          to amounts  expected  to be  realized,  based on enacted  tax laws and
          rates  applicable to the periods in which the differences are expected
          to affect  taxable  income.  Income tax  expense or benefit is the tax
          payable or refundable for the period,  plus or minus the change during
          the period in deferred tax assets and liabilities.

<PAGE>


INFORMEDICS, INC.
NOTES  TO FINANCIAL STATEMENTS


          Software Development Costs
          --------------------------

          Certain software development costs are being capitalized and amortized
          over the estimated  economic life of the software,  on a straight-line
          method,  commencing  when each product or enhancement is available for
          general release.  Amortization using the straight-line  method for the
          nine-month  periods  ended July 31,  1997 and 1996 was $ 181,561 and $
          141,213, respectively.

          Covenants Not to Compete
          ------------------------

          Covenants  not to  compete  are stated at the  estimated  value of the
          consideration given for the covenants  (including the present value of
          any future payments to be made under each agreement), less accumulated
          amortization. The costs of the covenants are being amortized over four
          or seven years, using the straight-line  method.  Amortization for the
          nine-month  periods  ended  July 31,  1997 and 1996 was $ 11,576 and $
          57,874, respectively.

          Loss Per Share
          --------------

          Loss per share is computed on the basis of weighted  average number of
          shares  outstanding  plus common stock  equivalents  which would arise
          from  the  exercise  of  stock  options  and  warrants.  Common  stock
          equivalents  are excluded from the  calculation  of net loss per share
          for the  nine  months  ended  July  31,  1997  and  1996,  as they are
          antidilutive.

          Cash and Cash Equivalents
          -------------------------

          The Company considers cash on hand, deposits in bank and highly liquid
          debt  instruments  purchased  with  original  maturity  dates of three
          months or less, as cash.

          Accounting Changes
          ------------------

          In October 1995, the Financial Accounting Standards Board (the "FASB")
          issued Statement of Financial  Accounting  Standards ("SFAS") No. 123,
          "Accounting for Stock-Based Compensation."  This statement establishes
          an  alternative  method of  accounting  that requires  recognizing  as
          expense the fair value of employee stock options and other stock-based
          awards at the grant date. SFAS No. 123 also allows the continuation of
          the current  accounting  treatment  under  which the Company  does not
          recognize  compensation  expense  for the stock  options  it awards to
          employees. Since the Company is electing to retain its current method,
          it will be  required  to  present  pro forma  disclosures  in its 1997
          annual financial statements as if the fair value based method had been
          applied.

          In February 1997, the FASB issued SFAS No. 128,  "Earnings per Share."
          SFAS 128,  requires all  companies  whose capital  structures  include
          convertible  securities  and  options to make a dual  presentation  of
          basic and diluted  earnings  per share (EPS) on the face of the income
          statement   and  requires   additional   disclosures   regarding   the
          computation  of EPS. The new standard  becomes  effective  for interim
          statements  issued after December 15, 1997. The effect on earnings per
          share for all periods reported is immaterial.
<PAGE>

          In June 1997, the FASB issued SFAS No. 130,  "Reporting  Comprehensive
          Income."  SFAS No. 130  establishes  requirements  for  disclosure  of
          comprehensive  income and becomes  effective for the Company's  fiscal
          year ending October 31, 1999.  Reclassification  of earlier  financial
          statements  for  comparative  purposes is required.  The impact on the
          Company's financial statements is not expected to be material.

          In June  1997,  the FASB  issued  SFAS  No.  131,  "Disclosures  about
          Segments  of an  Enterprise  and  Related  Information."  SFAS No. 131
          establishes  standards  for  disclosure  about  operating  segments in
          annual  financial  statements  and  selected  information  in  interim
          financial   reports.   It  also  establishes   standards  for  related
          disclosures  about products and services,  geographic areas, and major
          customers. This statement supersedes SFAS No. 14, "Financial Reporting
          for  Segments  of a Business  Enterprise."  The new  standard  becomes
          effective for the Company's  fiscal year ending  October 31, 1999, and
          requires that  comparative  information from earlier years be restated
          to conform to the requirements of this standard.

          Reclassifications
          -----------------

          Certain  prior year amounts have been  reclassified  to conform to the
          current year presentation.  These  reclassifications have no effect on
          net income.


2.        CREDIT AGREEMENTS

          In  April  1997 the  Company  renewed  its  revolving  line of  credit
          agreement with United States  National Bank of Oregon  ("USNB") in the
          amount of  $700,000.  The Company was not able to maintain its Debt to
          Tangible Net Worth covenant,  and as a result, the borrowing limit was
          reduced to $200,000 in August 1997. USNB agreed to waive this covenant
          through  October  31,  1997.  All assets of the Company are pledged as
          security  for the loan.  The  agreement  requires  the Company to make
          monthly  interest-only  payments on all amounts  outstanding under the
          agreement.  The interest rate is 2% above USNB's prime  interest rate.
          There was no amount  outstanding  under this  agreement as of July 31,
          1997. The agreement expires December 31, 1997.

3.         SUBSEQUENT EVENTS

          On July 29, 1997,  the Company signed a letter of intent to merge into
          Mediware Systems, Inc. of Melville,  NY. As described in the letter of
          intent,   the  proposed   merger  terms   provide  for  the  Company's
          stockholders  to receive  one share of  Mediware  stock for every four
          shares of Company  stock.  The merger is subject to  completion of due
          diligence,  execution of a definitive  agreement,  and approval by the
          Company's stockholders.

          The Company's  management recently determined that the benefit of the
          Company's  net  operating  loss  carryforwards  was not  likely  to be
          realized.  Accordingly,  during the current year the Company increased
          the valuation reserve to fully reserve the deferred tax asset relating
          to the net operating loss carryforwards.


<PAGE>


INFORMEDICS, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITIONS AND RESULTS OF OPERATIONS

THE FOLLOWING  DISCUSSION  INCLUDES CERTAIN  FORWARD-LOOKING  STATEMENTS.  THOSE
STATEMENTS INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES, WHICH COULD CAUSE ACTUAL
RESULTS  TO  DIFFER  MATERIALLY  FROM  THE  EXPECTATION  STATED,  INCLUDING  THE
FOLLOWING: SLOWER THAN EXPECTED SALES OF INFORMEDICS' PRODUCTS, DETERIORATION OF
BUSINESS  CONDITIONS  GENERALLY OR  SPECIFICALLY  IN THE  HEALTH-CARE  INDUSTRY,
REGULATORY CHANGES INVOLVING HEALTH CARE,  COMPETITIVE FACTORS,  PRICE PRESSURES
AND HIGHER THAN EXPECTED TURNOVER IN KEY PERSONNEL.

Highlights
----------

On July 29, 1997,  the Company  signed a letter of intent to merge into Mediware
Information  Systems,  Inc.  ("Mediware")  of Melville,  NY. As described in the
letter  of  intent,   the  proposed  merger  terms  provide  for  the  Company's
stockholders  to receive  one share of  Mediware  stock for every four shares of
Company stock.  The merger is subject to completion of due diligence,  execution
of  a  definitive  agreement,   and  approval  by  the  Company's  stockholders.
Management   believes  that  merging  the  two   companies   will  benefit  both
stockholders and customers by combining products, customer bases and resources.

On October  31,  1996,  the Company  sold  certain  assets of its  ClinicManager
product line to Adaptive  Health Systems of Washington,  Inc.  ("Adaptive").  In
April  1997  certain  conditions  of the sale were  satisfied,  resulting  in an
acceleration of the note receivable payments due from Adaptive.  On May 8, 1997,
the Company  received  $406,500 from  Adaptive to pay off the note.  The Company
recognized a gain of approximately  $166,000 during its third quarter ended July
31, 1997 relating to the funds received from Adaptive in May 1997.

The sale of the  ClinicManager  product  line and other  cost  cutting  measures
resulted in improved operating  results,  as the Company reduced its loss before
income  taxes for the third  quarter  and the first  nine  months of 1997,  when
compared to the same periods in 1996.  The loss before  income  taxes  decreased
from  $140,140 in third  quarter 1996 to $126,854 in third quarter 1997 and from
$770,740 for the first nine months of 1996 to $576,415 for the first nine months
of 1997.

The  elimination of the  ClinicManager  product line from the Company's  revenue
base  resulted  in a decrease in both  product  sales and  customer  service and
support  revenue for the third quarter and the first nine months of 1997.  Total
revenue decreased from $1,264,952 and $3,833,837 for the third quarter and first
nine months of 1996,  respectively,  to $722,145  and  $2,483,075  for the third
quarter and first nine months of 1997, respectively.

The Company's  management  recently determined that the benefit of the Company's
net operating  loss  carryforwards  was not likely to be realized.  Accordingly,
during the current year the Company  increased  the  valuation  reserve to fully
reserve the deferred tax asset relating to the net operating loss carryforwards.
The Company therefore wrote down the deferred asset by $688,025 during the third
quarter of 1997 which  resulted in an after tax loss for the quarter of $814,879
and a loss of $1,264,440 for the first nine months of 1997.

Results of Operations - Material Changes
----------------------------------------

The decrease in product  sales of $256,880 for third quarter 1997 as compared to
third  quarter 1996  resulted  from the loss of revenue  from the  ClinicManager
product  line,  reduced  sales of primary  product  Lifeline,  and a decrease in
clinic license fees for the Intramed.net  product. The decrease in product sales
of $650,228 for the first nine months of 1997  resulted from the loss of revenue
from the ClinicManager  product line and a decrease in laboratory system product
sales during 1997. In the second quarter of 1997,  the Company hired  additional
salespersons to increase  product sales in future periods.  Management  believes
that  products  sales for 1997 will  continue to lag 1996 results  until the new
sales of its  IntraMed.net  product  line exceed  previous  ClinicManager  sales
levels.
<PAGE>

The  decrease in customer  service and support  revenue of $285,927 and $700,534
for the third quarter and first nine months of 1997, respectively, when compared
to the  same  periods  in  1996,  resulted  from  a loss  of  revenue  from  the
ClinicManager  product line, a decrease in the number of customers who purchased
the  Company's  hardware  support  services  and a reduction in revenue from not
charging  laboratory  systems'  customers a regulatory  fee in 1997 as it did in
1996. In the second quarter of 1997, the Company began marketing a new technical
support  service to help  replace the  revenue  lost from the  hardware  support
services.  Management believes that customer service and support revenue for the
remainder of 1997 will be less than the comparable period in 1996.

A decrease in hardware  sales of $146,320 and $514,059 for the third quarter and
first nine months of 1997,  respectively,  resulted in a decrease in the cost of
products  sold.  The decrease in hardware  sales resulted from a loss of revenue
from the  ClinicManager  product  line,  a decrease in the number of  laboratory
systems  sold,  and a decrease in hardware  sales  related to the  Company's lab
order entry product line.

The decrease of $248,470  and  $769,342 in cost of customer  service and support
for the third quarter and first nine months of 1997, respectively, resulted from
a  reduction  in  staff  and  other  costs  as a  result  of  the  sale  of  the
ClinicManager product line. Management anticipates that cost of customer service
and support for the remainder of 1997 will be less than the comparable period in
1996.

The  increase of $17,294 in selling and  administration  expenses  for the third
quarter of 1997 compared to the third quarter of 1996,  resulted from  increases
in the sales and  marketing  costs offset in part by a decrease in rent expense.
The  increase in sales and  marketing  costs  resulted  from  hiring  additional
salespersons,  placing  more  advertisements  and  incurring  additional  travel
related costs to market the Company's  IntraMed.net  and LifeLine product lines.
However, management anticipates that selling and administration expenses will be
lower during the  remainder of 1997 than the  comparable  period in 1996, as the
Company continues its cost cutting measures.

Liquidity - Capital Resources
-----------------------------

The  Company's  cash  position  decreased  from  $323,217 on October 31, 1996 to
$259,154 on July 31, 1997, as the Company added  $175,251 of cash as a result of
operating  activities,  and used $114,314 for investing  activities and $125,000
for financing  activities.  As discussed earlier,  the Company received $406,500
from Adaptive on May 8, 1997 in full payment of the Company's  note  receivable.
Based  upon the  anticipation  of higher  product  sales and  reduced  operating
expenses,  management  believes  that the  Company's  current cash  position and
available funds under its revolving line of credit  agreement will be sufficient
to fund its  operating  and  investment  activities  for the remainder of fiscal
1997.

Continuing losses resulted in a negative working capital of $668,802 on July 31,
1997 as compared to a negative  working capital of $415,041 on October 31, 1996.
Excluding  the  deferred  revenue  liability,  which is a  liability  for future
services, the Company's working capital on July 31, 1997 was $583,985,  compared
to $859,846 on October 31, 1996.

Capital  expenditures  for  property  additions  were $40,019 for the first nine
months of 1997  compared  to  $69,921  for the first  nine  months of 1996.  The
decrease resulted from management's  decision to reduce capital  expenditures in
1997.  Management  anticipates that capital  expenditures for property additions
for the remainder of 1997 will continue to be less than 1996 amounts.

Capitalized  software development costs amounted to $86,884 and $159,990 for the
first nine months of 1997 and 1996, respectively. The decrease resulted from the
reduction of the software  development  costs associated with the  ClinicManager
product.  Management  anticipates that capitalized software development cost for
the remainder of 1997 will continue to be less than 1996 amounts.

In April 1997 the Company  renewed its $700,000  uncommitted  revolving  line of
credit with the Company's  bank.  There was no amount owing under this agreement
as of July 31, 1997. The Company was not able to maintain the required  covenant
ratios and as a result the  Company's  bank reduced the credit line to $200,000.
The Company's bank agreed to waive this covenant  through  October 31, 1997. All
of the assets of the Company are pledged as security for the line of credit. The
credit line agreement expires December 31, 1997.

<PAGE>


                                INFORMEDICS, INC.

                           Part II - Other Information




 Item 6.   Exhibits and Reports on Form 8-K

                    (a)  Exhibit.

                          27        Financial Data Schedule


                    (b)  Reports on Form 8-K

                          None


<PAGE>



                                   SIGNATURES



Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.



                                            INFORMEDICS, INC.
                                            (Registrant)


Date   September 12, 1997                   By /s/ John Tortorici
       -------------------                  -----------------------------------
                                            John Tortorici, Chairman, President,
                                            Chief Executive Officer and
                                            Chief Financial Officer


<PAGE>


                                   FORM 10-QSB

                                  Exhibit Index

Exhibit

         27       Financial Data Schedule